Table 1: Baseline characteristics of the three groups.
|
Parameter # |
‘H’ Patterns |
‘I’ Patterns |
‘A’ Patterns |
p * |
|
Median ± IQR |
Median (IQR) |
Median (IQR) |
Median (IQR) |
NS vs. CS vs. HA |
|
Age K/L-II |
|
|
|
0.997 |
|
Control group (NS) |
63 (62-64) |
62 (61-63) |
62 (61-63) |
|
|
IA-CS group (CS) |
63 (62-64) |
62 (61-63) |
|
|
|
IA-MMWHA (HA) |
62 (61-63) |
64 (63-66) |
62 (61-63) |
|
|
Age K/L-III |
|
|
|
|
|
Control group (NS) |
64 (63-65) |
63 (61-64) |
62 (61-63) |
|
|
IA-CS group (CS) |
62 (61-63) |
63 (62-64) |
|
|
|
IA-MMWHA (HA) |
64 (63-65) |
63 (62-64) |
63 (61-65) |
|
|
BMI K/L-II |
|
|
|
0.995 |
|
Control group (NS) |
24.5 (24-26) |
23.5 (22.5-24.2) |
23.0 (22.0-24.0) |
|
|
IA-CS group (CS) |
24.7 (23.2-26.2) |
24.5 (23.5-25.5) |
|
|
|
IA-MMWHA (HA) |
24.5 (23.5-26.5) |
24.7 (23.7-25.7) |
23.3 (22.3-24.3) |
|
|
BMI K/L-III |
|
|
|
|
|
Control group (NS) |
25.5 (24.0-27.0) |
25.0 (24.0-26.5) |
23.5 (22.5-24.5) |
|
|
IA-CS group (CS) |
25.9 (25.2-27.0) |
25.5 (24.5-27.5) |
|
|
|
IA-MMWHA (HA) |
25.5 (25.0-27.0) |
24.5 (24.0-26.0) |
24.0 (23.5-25.5) |
|
|
Gender K/L-II |
|
|
|
1.000 |
|
Control group (NS) |
♀-15/♂-10 |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
IA-CS group (CS) |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
|
IA-MMWHA (HA) |
♀-15/♂-10 |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
Gender K/L-III |
|
|
|
|
|
Control group (NS) |
♀-15/♂-10 |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
IA-CS group (CS) |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
|
IA-MMWHA (HA) |
♀-15/♂-10 |
♀-15/♂-10 |
♀-15/♂-10 |
|
|
PW (VAS mm.) K/L-II |
0.993 |
|||
|
Control group (NS) |
41 (39-42) |
43 (42-44) |
45 (44-47) |
|
|
IA-CS group (CS) |
41 (40-42) |
43 (41-45) |
|
|
|
IA-MMWHA (HA) |
41 (39-42) |
43 (41-45) |
45 (43-48) |
|
|
PW (VAS mm.) K/L-III |
||||
|
Control group (NS) |
48 (47-49) |
50󠄀 (49-52) |
52 (51-54) |
|
|
IA-CS group (CS) |
48 (47-49) |
50 (48-52) |
|
|
|
IA-MMWHA (HA) |
48 (47-50) |
50 (48-53) |
53(52-55) |
|
|
F (WOMAC-C) K/L-II |
0.953 |
|||
|
Control group (NS) |
32 (31-33) |
33 (32-35) |
36 (35-37) |
|
|
IA-CS group (CS) |
32 (31-33) |
34 (32-36) |
|
|
|
IA-MMWHA (HA) |
31 (31-33) |
34 (32-36) |
36 (34-37) |
|
|
F (WOMAC-C) K/L-III |
||||
|
Control group (NS) |
38 (37-39) |
41 (39-42) |
43 (42-44) |
|
|
IA-CS group (CS) |
38 (37-39) |
41 (39-42) |
|
|
|
IA-MMWHA (HA) |
38 (36-40) |
41 (39-43) |
43 (41-45) |
|
|
s-CTX-I (ng/mL) K/L-II |
|
|
|
0.913 |
|
Control group (NS) |
520 (460-600) |
590 (530-650) |
650 (600-700) |
|
|
IA-CS group (CS) |
520 (470-590) |
580 (520-640) |
|
|
|
IA-MMWHA (HA) |
525 (465-600) |
595 (530-660) |
655 (610-700) |
|
|
s-CTX-I (ng/mL) K/L-III |
|
|
|
|
|
Control group (NS) |
560 (500-620) |
645 (600-700) |
715 (650-780) |
|
|
IA-CS group (CS) |
555 (500-610) |
650 (600-700) |
|
|
|
IA-MMWHA (HA) |
564 (510-620) |
654 (604-700) |
720 (660-790) |
|
|
u-CTX-II (ng/mmol Cr) K/L-II |
|
|
|
0.912 |
|
Control group (NS) |
346 (300-390) |
378 (330-415) |
456 (416-496) |
|
|
IA-CS group (CS) |
350 (295-390) |
375 (325 -420) |
|
|
|
IA-MMWHA (HA) |
354 (304-394) |
382 (334-420) |
464 (420-500) |
|
|
u-CTX-II (ng/mmol Cr) K/L-III |
|
|
|
|
|
Control group (NS) |
378 (318-438) |
418 (350-478) |
476 (426-526) |
|
|
IA-CS group (CS) |
380 (320-435) |
415 (350-475) |
|
|
|
IA-MMWHA (HA) |
384 (324-442) |
423 (353-483) |
484 (430-530) |
|
|
mJSW (mm.) K/L-II |
0.956 |
|||
|
Control group (NS) |
4.4 (3.9-4.9) |
4.3 (4.0-4.6) |
4.2 (3.8-4.6) |
|
|
IA-CS group (CS) |
4.4 (3.9-4.9) |
4.3 (3.8-4.8) |
|
|
|
IA-MMWHA (HA) |
4.4 (4.0-4.8) |
4.3 (3.9-4.7) |
4.2 (3.8-4.6) |
|
|
mJSW (mm.) K/L-III |
||||
|
Control group (NS) |
3.6 (3.1-4.1) |
3.5 (3.0-4.0) |
3.4 (2.9-3.9) |
|
|
IA-CS group (CS) |
3.6 (3.1-4.1) |
3.5 (3.0-4.0) |
|
|
|
IA-MMWHA (HA) |
3.6 (3.2-4.0) |
3.5 (3.1-3.9) |
3.4 (3.0-3.8) |
|
|
AP spine L1-L4 BMD (g/cm2) K/L-II |
0.948 |
|||
|
Control group (NS) |
1.3 (1.0-1.5) |
1.1 (0.9-1.3) |
0.8 (0.7-0.9) |
|
|
IA-CS group (CS) |
1.3 (1.0-1.6) |
1.1 (0.9-1.3) |
|
|
|
IA-MMWHA (HA) |
1.3 (1.1-1.5) |
1.1 (0.8-1.4) |
0.8 (0.6-0.9) |
|
|
AP spine L1-L4 BMD (g/cm2) K/L-III |
||||
|
Control group (NS) |
1.0 (0.8-1.2) |
0.8 (0.5-1.1) |
0.6 (0.5-0.7) |
|
|
IA-CS group (CS) |
1.1 (0.9-1.3) |
0.8 (0.6-1.1) |
|
|
|
IA-MMWHA (HA) |
1.0 (0.9-1.2) |
0.8 (0.6-1.0) |
0.6 (0.53-0.67) |
|
|
Total hip BMD (g/cm2) K/L-II |
0.947 |
|||
|
Control group (NS) |
0.8 (0.6-1.0) |
0.6 (0.5-0.7) |
0.45 (0.39-0.51) |
|
|
IA-CS group (CS) |
0.8 (0.7-1.0) |
0.6 (0.55-0.7) |
|
|
|
IA-MMWHA (HA) |
0.8 (0.7-0.9) |
0.6 (0.5-0.65) |
0.45 (0.38-0.51) |
|
|
Total hip BMD (g/cm2) K/L-III |
||||
|
Control group (NS) |
0.71 (0.61-0.81) |
0.51 (0.43-0.60) |
0.35 (0.32-0.38) |
|
|
IA-CS group (CS) |
0.73 (0.63-0.83) |
0.52 (0.42-0.62) |
|
|
|
IA-MMWHA (HA) |
0.72 (0.62-0.82) |
0.5 (0.41-0.61) |
0.35 (0.33-0.37) |
|
|
Femoral neck BMD (g/cm2) K/L-II |
0.946 |
|||
|
Control group (NS) |
0.9 (0.8-1.0) |
0.7 (0.6-0.8) |
0.5 (0.4-0.6) |
|
|
IA-CS group (CS) |
0.92 (0.75-1.1) |
0.73 (0.61-0.8) |
|
|
|
IA-MMWHA (HA) |
0.9 (0.7-1.1) |
0.7 (0.62-0.78) |
0.5 (0.43-0.57) |
|
|
Femoral neck BMD (g/cm2) K/L-III |
||||
|
Control group (NS) |
0.81 (0.67-0.91) |
0.63 (0.6-0.68) |
0.4 (0.36-0.44) |
|
|
IA-CS group (CS) |
0.82 (0.7-0.92) |
0.64 (0.6-0.7) |
|
|
|
IA-MMWHA (HA) |
0.8 (0.7-0.9) |
0.63 (0.6-0.67) |
0.42 (0.38-0.44) |
|
|
Total body BMD (g/cm2) K/L-II |
|
|
|
0.945 |
|
Control group (NS) |
1.5 (1.3-1.7) |
1.4 (1.3-1.5) |
1.3 (1.2-1.4) |
|
|
IA-CS group (CS) |
1.6 (1.3-1.9) |
1.4 (1.3-1.6) |
|
|
|
IA-MMWHA (HA) |
1.5 (1.4-1.6) |
1.4 (1.2-1.6) |
1.3 (1.1-1.5) |
|
|
Total body BMD (g/cm2) K/L-III |
|
|
|
|
|
Control group (NS) |
1.4 (1.3-1.5) |
1.3 (1.2-1.4) |
1.2 (1.1-1.3) |
|
|
IA-CS group (CS) |
1.4 (1.3-1.6) |
1.3 (1.2-1.5) |
|
|
|
IA-MMWHA (HA) |
1.4 (1.2-1.6) |
1.3 (1.1-1.5) |
1.2 (1.0-1.4) |
#- Each study subgroup included 25 subjects; *-All interim comparisons were performed with Kruskal-Wallis test followed by Dunn-Bonferroni post hoc for the final analyses; PW- Pain at walking by visual analogue scale; F (WOMAC-C) - Functional ability by WOMAC function scale; s-CTX-I - Serum CTX-I, the values are given in nanogram per milliliter; u-CTX-II - Urine CTX-II, the values are given as corrected concentration of uctx-II for urinary creatinine concentration in ng/mmol Cr; mJSW-mean joint space width.